SEC Declares Form S-4 Registration Statement “Effective” for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.
Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting…
Comments Off on SEC Declares Form S-4 Registration Statement “Effective” for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.